Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens
| Autor: | Fiona M, Behan, Francesco, Iorio, Gabriele, Picco, Emanuel, Gonçalves, Charlotte M, Beaver, Giorgia, Migliardi, Rita, Santos, Yanhua, Rao, Francesco, Sassi, Marika, Pinnelli, Rizwan, Ansari, Sarah, Harper, David Adam, Jackson, Rebecca, McRae, Rachel, Pooley, Piers, Wilkinson, Dieudonne, van der Meer, David, Dow, Carolyn, Buser-Doepner, Andrea, Bertotti, Livio, Trusolino, Euan A, Stronach, Julio, Saez-Rodriguez, Kosuke, Yusa, Mathew J, Garnett |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Gene Editing
Werner Syndrome Helicase Genome Human Reproducibility of Results Mice Organ Specificity Cell Line Tumor Neoplasms Drug Discovery Biomarkers Tumor Animals Humans Female Microsatellite Instability Molecular Targeted Therapy Werner Syndrome CRISPR-Cas Systems Synthetic Lethal Mutations Neoplasm Transplantation |
| Popis: | Functional genomics approaches can overcome limitations-such as the lack of identification of robust targets and poor clinical efficacy-that hamper cancer drug development. Here we performed genome-scale CRISPR-Cas9 screens in 324 human cancer cell lines from 30 cancer types and developed a data-driven framework to prioritize candidates for cancer therapeutics. We integrated cell fitness effects with genomic biomarkers and target tractability for drug development to systematically prioritize new targets in defined tissues and genotypes. We verified one of our most promising dependencies, the Werner syndrome ATP-dependent helicase, as a synthetic lethal target in tumours from multiple cancer types with microsatellite instability. Our analysis provides a resource of cancer dependencies, generates a framework to prioritize cancer drug targets and suggests specific new targets. The principles described in this study can inform the initial stages of drug development by contributing to a new, diverse and more effective portfolio of cancer drug targets. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|